Snehal Patel Purchases 2,900 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,900 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average price of $27.54 per share, with a total value of $79,866.00. Following the transaction, the chief executive officer owned 5,602,302 shares in the company, valued at $154,287,397.08. This represents a 0.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Tuesday, January 13th, Snehal Patel bought 1,800 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $29.83 per share, with a total value of $53,694.00.
• On Wednesday, December 31st, Snehal Patel purchased 4,300 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $21.36 per share, with a total value of $91,848.00.
• On Tuesday, December 30th, Snehal Patel purchased 2,900 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $21.73 per share, for a total transaction of $63,017.00.
• On Thursday, December 18th, Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $12.62 per share, with a total value of $51,742.00.
• On Tuesday, November 25th, Snehal Patel bought 4,600 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $8.37 per share, for a total transaction of $38,502.00.
• On Friday, November 7th, Snehal Patel purchased 10,600 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $8.43 per share, for a total transaction of $89,358.00.
• On Friday, October 31st, Snehal Patel purchased 2,300 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $9.26 per share, with a total value of $21,298.00.

Greenwich LifeSciences Stock Down 7.2%

Shares of NASDAQ:GLSI opened at $27.19 on Friday. The firm has a market cap of $376.58 million, a price-to-earnings ratio of -18.62 and a beta of 1.47. Greenwich LifeSciences, Inc. has a 12 month low of $7.78 and a 12 month high of $32.91. The company’s fifty day simple moving average is $14.04 and its 200 day simple moving average is $11.94.

Greenwich LifeSciences (NASDAQ:GLSI) last released its earnings results on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.30). Research analysts expect that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on GLSI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, December 27th. Finally, HC Wainwright boosted their price objective on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $47.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth approximately $25,000. Vanguard Group Inc. increased its holdings in Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock worth $2,808,000 after buying an additional 13,179 shares during the last quarter. Citadel Advisors LLC increased its holdings in Greenwich LifeSciences by 52.1% during the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock worth $208,000 after buying an additional 7,174 shares during the last quarter. Bank of America Corp DE raised its position in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after acquiring an additional 1,322 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Greenwich LifeSciences in the first quarter valued at $177,000. 4.16% of the stock is currently owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.